Indian pharma firms have little reason to fear Trump's tariff threat
Trump's pledge to apply 100% levy on firms making off-patent medications by 2028 (rising to 200% a year later) unless they move production to US faces formidable commercial and political obstacles
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
